GTB-5550

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameGTB-5550
Drug Alias NameGTB-5550B7H3 TriKE™cam1615B7H3GTB-5550 TriKE™
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody) +[4] 
Mechanisms of ActionAnti-Low affinity immunoglobulin gamma Fc region receptor III-AAnti-CD276Natural killer cells stimulants +[5] 
TargetsLow affinity immunoglobulin gamma Fc region receptor III-ACD276 antigenInterleukin-15
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MinnesotaMasonic Cancer Center, University Of MinnesotaGt Biopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A